SDH-deficient kidney tumors are likely to be as sensitive to glucose as FH-deficient tumors and targeting the vasculature or glucose transport in these tumors may provide a novel approach to disrupt the fundamental metabolic machinery of these aggressive cancers. Here, FH is linked to cancer.